argenx SE
ARGXNext catalyst
Efgartigimod
generalized myasthenia gravis
Get an email about ARGX's next catalysts
Track argenx (ARGX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 10 more upcoming events in our data (PDUFA date, Phase 3 readout, Phase 2 readout).See the timeline
12 upcoming, 2 past
FDA PDUFA Date efgartigimod alfa-fcab (priority)
For generalized myasthenia gravis. BLA filing. Extracted from SEC filing: 6-K
Sourceefgartigimod administration Phase 3 Est. Readout
Estimated primary completion for efgartigimod administration trial (NCT06765161) in Myasthaenia Gravis. Topline data typically follows completion by weeks to months.
Phase III Vyvgart Sjögren's study discontinued due to predicted efficacy failure
SourceFDA PDUFA Date VYVGART and VYVGART Hytrulo (efgartigimod alfa) (priority)
For pediatric generalized myasthenia gravis (gMG). sNDA filing. Extracted from SEC filing: EX-99.1
SourceEfgartigimod IV Phase 3 Est. Readout (ADAPT Jr)
Estimated primary completion for Efgartigimod IV trial (NCT04833894) in Generalized Myasthenia Gravis. Topline data typically follows completion by weeks to months.
SourceEfgartigimod PH20 SC Phase 2 Est. Readout (ADHERE+)
Primary completion for Efgartigimod PH20 SC trial (NCT04280718) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SourceEfgartigimod Alfa Phase 2 Est. Readout (PET-AON)
Estimated primary completion for Efgartigimod Alfa trial (NCT06453694) in Optic Neuritis. Topline data typically follows completion by weeks to months.
SourceEfgartigimod PH20 SC Phase 3 Est. Readout (Unity)
Primary completion for Efgartigimod PH20 SC trial (NCT06684847) in Primary Sjogrens Disease
SourceEfgartigimod PH20 SC Phase 3 Est. Readout (ADAPT Jr SC)
Estimated primary completion for Efgartigimod PH20 SC trial (NCT06392386) in Generalized Myasthenia Gravis. Topline data typically follows completion by weeks to months.
SourceUpcoming FDA decisions
How ARGX's past catalysts played out
Market Overview
Stock performance and key metrics
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.
WebsiteEmpasiprubart IV
Chronic Inflammatory Demyelinating Polyneuropathy
IVIG (Intravenous Immunoglobulin)
Multifocal Motor Neuropathy (MMN)
Efgartigimod
Postural Orthostatic Tachycardia Syndrome
empasiprubart
Chronic Inflammatory Demyelinating Polyneuropathy
efgartigimod administration
Myasthaenia Gravis
ARGX-113
Pemphigus Vulgaris
Efgartigimod PH20 SC
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
EFG PH20 SC
Active Idiopathic Inflammatory Myopathy
Efgartigimod IV
Generalized Myasthenia Gravis
AZA
Leukemia, Myeloid, Acute
Efgartigimod PH20 (ARGX-113) SC
Autoimmune Encephalitis (AE)
efgartigimod PH20 SC in stage B
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
ARGX-119
Amyotrophic Lateral Sclerosis
ARGX-117
Multifocal Motor Neuropathy
ARGX-119 IV
Spinal Muscular Atrophy (SMA)
ARGX-121
Immunoglobulin A Nephropathy (IgAN)
ARGX-110
Leukemia, Myeloid, Acute
Efgartigimod Alfa
Optic Neuritis
Cusatuzumab
Leukemia, Myeloid, Acute
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Empasiprubart IV | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
IVIG (Intravenous Immunoglobulin) | Phase 3 | Multifocal Motor Neuropathy (MMN) | - | - |
Efgartigimod | Phase 3 | Postural Orthostatic Tachycardia Syndrome | - | - |
empasiprubart | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
efgartigimod administration | Phase 3 | Myasthaenia Gravis | - | - |
ARGX-113 | Phase 3 | Pemphigus Vulgaris | - | - |
Efgartigimod PH20 SC | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
EFG PH20 SC | Phase 3 | Active Idiopathic Inflammatory Myopathy | - | - |
Efgartigimod IV | Phase 3 | Generalized Myasthenia Gravis | - | - |
AZA | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Efgartigimod PH20 (ARGX-113) SC | Phase 2 | Autoimmune Encephalitis (AE) | - | - |
efgartigimod PH20 SC in stage B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | - | - |
ARGX-119 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
ARGX-117 | Phase 2 | Multifocal Motor Neuropathy | - | - |
ARGX-119 IV | Phase 2 | Spinal Muscular Atrophy (SMA) | - | - |
ARGX-121 | Phase 2 | Immunoglobulin A Nephropathy (IgAN) | - | - |
ARGX-110 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Efgartigimod Alfa | Phase 2 | Optic Neuritis | - | - |
Cusatuzumab | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Sjögren's disease
1 drug in this indication
Sjogren's syndrome
1 drug in this indication
Sjögren's syndrome
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in argenx SE's drug pipeline?→
CatalystAlert tracks 19 drug candidates in argenx SE's (ARGX) pipeline across Phase 3, Phase 2. Its lead program is Efgartigimod (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is argenx SE's next FDA catalyst?→
argenx SE's (ARGX) next tracked catalyst is a PDUFA date expected Jan 3, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARGX biotech catalysts?→
Add ARGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow argenx SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
